Cryo Cell International Inc: Form 10-Q for the period ended May 31, 2018
Filed with the SEC on Jul 16, 2018 and accepted by EDGAR at Jul 16, 2018, 21:23 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-05-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-03-09 to 2018-05-31 | $6.5m | us-gaap:Revenues |
| Revenue | 6 months2017-12-01 to 2018-05-31 | $12.8m | us-gaap:Revenues |
| Research and development | 3 months2018-03-09 to 2018-05-31 | $29.3k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2017-12-01 to 2018-05-31 | $42.7k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2018-03-09 to 2018-05-31 | $3.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2017-12-01 to 2018-05-31 | $7.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2018-03-09 to 2018-05-31 | $1.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-12-01 to 2018-05-31 | $2.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-03-09 to 2018-05-31 | $304.1k | us-gaap:InterestExpense |
| Interest expense | 6 months2017-12-01 to 2018-05-31 | $585.1k | us-gaap:InterestExpense |
| Income tax | 3 months2018-03-09 to 2018-05-31 | $315.9k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2017-12-01 to 2018-05-31 | $3.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-03-09 to 2018-05-31 | $539.5k | us-gaap:NetIncomeLoss |
| Net income | 6 months2017-12-01 to 2018-05-31 | −$2.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-03-09 to 2018-05-31 | $0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2017-12-01 to 2018-05-31 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-03-09 to 2018-05-31 | $0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2017-12-01 to 2018-05-31 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-03-09 to 2018-05-31 | 7,917,735 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2017-12-01 to 2018-05-31 | 7,177,082 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2017-12-01 to 2018-05-31 | $1.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2017-12-01 to 2018-05-31 | $253.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-05-31 | $6.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-05-31 | $13.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-05-31 | $22.2m | us-gaap:Assets |
| Current liabilities | At period end2018-05-31 | $12.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-05-31 | $36.3m | us-gaap:Liabilities |
| Long-term debt | At period end2018-05-31 | $1.4m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2018-05-31 | −$14.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-18-218864. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.